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Background/aim: The present study aimed to define the clinical and laboratory criteria for predicting patients that will not benefit from
invasive mechanical ventilation (IMV) treatment and determine the prediction of mortality and prognosis of these critical ill patients.
Materials and methods: The study was designed as an observational, multicenter, prospective, and cross-sectional clinical study. It was
conducted by 75 researchers at 41 centers in intensive care units (ICUs) located in various geographical areas of Turkey. It included a total
of 1463 ICU patients who were receiving invasive mechanical ventilation (IMV) treatment. A total of 158 parameters were examined
via logistic regression analysis to identify independent risk factors for mortality; using these data, the IMV Mortality Prediction Score
(IMPRES) scoring system was developed.
Results: The following cut-off scores were used to indicate mortality risk: <2, low risk; 2–5, moderate risk; 5.1–8, high risk; >8, very high
risk. There was a 26.8% mortality rate among the 254 patients who had a total IMPRES score of lower than 2. The mortality rate was
93.3% for patients with total IMPRES scores of greater than 8 (P < 0.001).
Conclusion: The present study included a large number of patients from various geographical areas of the country who were admitted
to various types of ICUs, had diverse diagnoses and comorbidities, were intubated with various indications in either urgent or elective
settings, and were followed by physicians from various specialties. Therefore, our data are more general and can be applied to a broader
population. This study devised a new scoring system for decision-making for critically ill patients as to whether they need to be intubated
or not and presents a rapid and accurate prediction of mortality and prognosis prior to ICU admission using simple clinical data.
Key words: Critical care, ethics, intubation, invasive mechanical ventilation, scoring systems, prediction

1. Introduction
Mortality rates in adult ICUs range from 30% to 65% [1–5].
Invasive mechanical ventilation (IMV) is often necessary
during the course of serious acute pathologies such as
traumas, intoxications, and infections, as well as during
the course of chronic diseases such as neuromuscular

disorders, chronic obstructive pulmonary disease
(COPD), and interstitial lung diseases [6–8]. The criteria
for intensive care unit (ICU) admission and discharge
as well as indications for IMV treatment have been
established [9,10]. However, not all patients undergoing
IMV benefit from this treatment. For such cases, IMV only
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helps to postpone mortality. The suspended animation
state that will inevitably result in death is often spent in a
sedated, comatose, and completely passive condition with
a very low quality of life, which can be quite tormenting
for the patient. Since patients requiring IMV are often
admitted to the ICU, a significant number of the limited
beds in ICUs are often occupied by patients who will not
survive. Because of this, many patients with reversible
conditions requiring ICU care will not have access to ICU
support. Moreover, comatose patients receiving IMV can
make it difficult to control serious problems in the ICU,
such as nosocomial infections. Further, the relatives of
these patients often have irrational hopes for recovery,
which leads to prolonged IMV treatment. Many countries
commonly practice the orders “do not resuscitate” (DNR)
and “do not intubate” (DNI), meaning that either the
patient or his/her custodian had decided to forego lifeprolonging treatment when resuscitation is not expected
to change the survival outcome [11]. For instance, in
Taiwan, if a patient older than the age of 20 provides a
written statement acknowledging his/her will to abandon
medical treatment, then according to the Natural Death
Act (passed in the year 2000), that patient’s doctor is not
subject to legal sanction. However, DNR documents and
other advance orders are not yet part of standard medical
practices in low-income countries [12].
In this regard, the accurate prediction of patients
that will most likely benefit from IMV is very important
for clinicians when justifying IMV in emergency
departments, clinics, or, sometimes at the scene of the
event. Unfortunately, to our knowledge, there are no
evidence-based and tangible criteria used for defining
patients that will not benefit from IMV. Such criteria
would save clinicians from ethical dilemmas and protect
them in judicial processes.
In the current study, we aimed to define criteria that
will help to objectively identify patients that will not
benefit from IMV treatment. With these criteria, we hope
to eliminate the impact of subjective personal anticipation,
the insistence and pressures of patients’ relatives, and
local-cultural determinants. We hope that this study will
serve to ease clinicians’ decision-making processes in
the face of jurisdiction, patients’ relatives, and their own
conscience, as well as aiding in objective decision-making
and facilitating the more rational use of ICU beds.
2. Materials and methods
2.1. Study design
The STROBE guidelines were used as a guide for this
manuscript. This study was designed as an observational,
multicenter, prospective, and cross-sectional clinical study.
The scientific ethical committee of Karadeniz Technical
University’s Faculty of Medicine granted ethical approval

for this study. Patients/custodians and researchers
provided written consent prior to participation in this
study. Researchers from various ICUs in Turkey who
accepted the invitation that was distributed nationwide
(via e-mail) were enrolled in the study. An online meeting
was held among the participating researchers to establish
the study protocol and the data collection form. The results
were evaluated in an e-mail group that included all of the
researchers, and the current manuscript was composed in
accordance with the opinions and recommendations of all
of the researchers.
2.2. Patients and setting
This study included patients who were receiving IMV
treatment in ICUs. This was completely an observational
study, and no extra interventions were applied to the
patients. Bedside data collection forms that were created
specifically for this study were filled out by researchers
for all patients who stayed in the ICU for more than 24 h
and received IMV support. At the end of each month, data
from patients who were discharged from the ICU within
that month were collected from every center. Patients who
died during their ICU stay were categorized as the group
that did not benefit from IMV, while the surviving patients
(e.g., transferred to a ward, discharged to home, referred,
etc.) were categorized as the group that benefited from
IMV. This study excluded patients who were admitted to
the pediatric ICU, neonatal ICU, or postanesthesia care
units and those who were younger than 18 years old. For
every patient, we collected demographical data, the type of
the ICU to which they were admitted, primary indications
for ICU admission, comorbid diseases, place of intubation
(i.e. event scene, emergency department, hospital ward,
ICU, other), urgency of intubation (i.e. urgent, elective),
and the physician who decided on intubation and
intubation indications. Additionally, we evaluated the
possible patient-related factors that were considered by the
physician as an indicator that IMV would most likely not
benefit a patient (Table 1) [1,13].
For all patients, we recorded the condition at discharge
(e.g., exitus, successful weaning/extubation, mechanical
ventilation
dependence/tracheostomy,
referral),
reintubation requirement, mechanical ventilation duration,
and ICU stay length. On the first day of ICU admission,
we calculated the Acute Physiology and Chronic Health
Evaluation-II (APACHE-II) and Sequential Organ Failure
Assessment (SOFA) scores for each patient [14,15].
2.3. Statistical analysis
All data for this study were analyzed with IBM SPSS
23 statistics software. The Shapiro–Wilk test was used
to determine the normality of the numerical data.
Nonnormally distributed numerical data were analyzed
with the Mann–Whitney U test via nonparametric
methods. Comparisons of categorical data were made with
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Table 1. Possible patient-related factors suggesting that the patient will most likely not benefit from IMV treatment [1,13].
Serious comorbidity (one or more)
Advanced age
Low chance of recovery despite the benefits gained
Low chance for life-prolonging treatment
Bed-bound for the long term (>3 months)
Terminal stage of chronic disease/malignancy
Life expectancy shorter than 6 months
Permanent multiorgan failure
Malignancy refractory to previous chemotherapy/radiotherapy
Recurring ICU requirement due to development of serious organ failure following discharge from previous prolonged ICU admission
High treatment cost in proportion to the benefits gained
IMV requirement in an immunosuppressed patient as a result of the primary disease
Newly diagnosed patient who is unlikely to tolerate chemotherapy treatment

the Pearson chi-square test. Independent risk factors for
mortality were determined with binary logistic regression
analysis. For those risk factors found to be significant via
logistic regression analysis, odds ratio (OR) values were
used to calculate the IMV Mortality Prediction Score
(IMPRES). The chi-square test was used to compare
mortality rates among groups after risk stratification.
Numerical data were expressed as medians (min–max),
while categorical data were presented as frequencies
(percentages). Values of P < 0.05 were considered
significant.
3. Results
3.1. General patient characteristics
The study was conducted with the participation of 75
researchers from 41 distinct centers (universities, training
and research hospitals, or state hospitals) located in
various geographical areas of Turkey. Data collection was
performed from 1 January 2017 to 30 April 2017. A total of
1463 patients receiving IMV treatment in 11 different types
of ICUs located in these centers during the study period
were enrolled in this study. Of these patients, 625 (42.7%)
were female and 838 (57.3%) were male. The median
patient age was 71 years (18–101 years), and the median
body mass index (BMI) was 26 kg/m2 (14–76 kg/m2). Of
the patients, 639 (43.7%) were from university hospitals,
530 (36.2%) were from training and research hospitals,
220 (15%) were from state hospitals, and 74 (5.1%) were
from private hospitals. Of the patients, 762 (52.1%) were
followed by attending physicians other than an ICU
specialist, 397 (27.2%) were followed by an ICU specialist/
fellowship trainer, and 304 (20.8%) were followed by an
ICU physician in-chief. The type of ICU was general ICU
for 429 (29.3%) patients, anesthesiology and reanimation
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ICU for 268 (18.3%) patients, medical ICU for 210
(14.4%) patients, and pulmonary diseases ICU for 154
(10.5%) patients. Other ICU types included surgical ICUs,
emergency departments, and neurological, neurosurgical,
internal diseases, coronary, and cardiovascular ICUs. Table
2 presents the clinical features of the patients.
Of the patients, 823 (56.3%) were intubated in an urgent
condition, while 640 (43.7%) were intubated in an elective
condition. The most common place where intubation was
performed was ICUs (797 (54.5%) patients), followed by
emergency departments (393 (26.9%) patients), hospital
wards (156 (10.7%) patients), event scene (57 (3.9%)
patients), and other locations (60 (4.0%) patients). During
their ICU stay, 197 (13.5%) patients required reintubation.
With regard to patient outcomes, 880 (60.2%) patients died
during their ICU stay, while the rest of the patients were
discharged from the ICU with the following conditions:
successful weaning/extubation (368 (25.2%) patients),
mechanical ventilator dependence/tracheostomy (168
(11.5%) patients), and referral or transfer to other ICUs
(47 (3.2%) patients).
When comparing the nonsurvival and survival groups,
patient age was significantly higher in the mortality group
(P < 0.001). However, there was no difference in mortality
rate between the sexes (P = 0.161). Patient mortality was
also evaluated according to the acute conditions presenting
as ICU admission indications. While mortality rates were
lower among patients with type II (P = 0.026) and type
III respiratory failure (P < 0.001), they were significantly
higher among those admitted to the ICU after successful
cardiopulmonary resuscitation (P < 0.001), circulatory
shock (P < 0.001), distributive shock (P = 0.016),
circulatory failure (P = 0.013), and severe electrolyte
imbalance (P < 0.001). The diagnosis of type I respiratory
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Table 2. Characteristic features of the patients included in this study.
n (%)
Primary indication for admission

n (%)
Comorbidities

Pneumonia

415 (28.37)

Hypertension

536 (36.64)

COPD exacerbation

247 (16.88)

Heart failure

326 (22.28)

Acute renal failure

229 (15.65)

Diabetes mellitus

306 (20.92)

Heart failure

201 (13.74)

COPD

266 (18.18)

Cardiac arrest

179 (12.24)

Coronary arterial disease

264 (18.05)

Sepsis

165 (11.28)

None

182 (12.44)

Cerebrovascular ischemia

152 10.39)

Arrhythmia

165 (11.28)

Chronic renal disease

102 (6.97)

CVA

148 (10.12)

Aspiration

96 (6.56)

Alzheimer’s disease

118 (8.07)

Cerebrovascular hemorrhage

94 (6.43)

Chronic renal failure

108 (7.38)

Pulmonary edema

92 (6.29)

Lung cancer

65 (4.44)

Hyper/hypotension

85 (5.81)

Chronic renal disease

39 (2.67)

Lung malignancy

77 (5.26)

Asthma

34 (2.32)

Arrhythmia tachy/bradycardia

73 (4.99)

Heart valvular disease

30 (2.05)

Acute coronary syndrome

62 (4.24)

Hyper/hypothyroidism

26 (1.78)

Coronary arterial disease

47 (3.21)

Colon/intestinal cancer

25 (1.71)

Post-operative (elective)

43 (2.94)

Epilepsy

25 (1.71)

Multiple trauma

42 (2.87)

Other

428 (29.25)

Pulmonary embolism

42 (2.87)

Acute indication for ICU admission

Intracranial trauma

41 (2.80)

Type I respiratory failure

518 (35.41)

ARDS

40 (2.73)

Deteriorating GCS

438 (29.94)

Other

757 (51.74)

Type II respiratory failure

417 (28.50)

Indication for intubation

Cardiopulmonary resuscitation

283 (19.34)

Insufficient oxygenation/hypoxemia

656 (44.8)

Hypotensive shock

133 (9.09)

Orientation-cooperation disturbance

516 (35.3)

Circulatory shock

84 (5.74)

Insufficient ventilation/hypercapnia

479 (32.7)

Severe electrolyte imbalance

83 (5.67)

Respiratory arrest

316 (21.6)

Circulatory failure

76 (5.19)

Cardiac arrest

299 (20.4)

Major hemorrhage

44 (3.01)

NIV failure

208 (14.2)

Type III respiratory failure

44 (3.01)

Severe metabolic acidosis

117 (8.0)

Distributive shock

28 (1.91)

Control of pulmonary secretions

109 (7.5)

Neurogenic shock

19 (1.30)

Other

105 (7.17)

Brain death – possible donor

9 (0.62)

Other

55 (3.76)

All indications are not shown in the table.
Indications are listed in order of frequency (%).
COPD: Chronic obstructive pulmonary disease, ARDS: acute respiratory distress syndrome, NIV: noninvasive ventilation, CVA:
cerebrovascular accident, GCS: Glasgow Coma Score.

failure did not cause any significant difference in mortality
(P = 0.165). In terms of intubation indications, mortality
was seen in 219 (73.2%) of 299 patients intubated after
cardiac arrest (P < 0.001) and in 106 (51%) of 208 patients

intubated after a failed attempt at noninvasive ventilation
(NIV) (P = 0.003). The mortality rate did not differ
according to whether the intubation was performed in
an urgent or elective condition. Mortality was seen in 500
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(60.8%) of 823 patients intubated in urgent settings and in
380 (59.4%) of 640 patients intubated in elective settings
(P = 0.401). Characteristic properties of patients in the
nonsurvival and survival groups are presented in Table 3.
3.2. A novel scoring system for the prediction of ICU
mortality: IMV Mortality Prediction Score (IMPRES)
A total of 158 parameters were examined via logistic
regression analysis with the backward Wald method. The
variables that were identified as independent risk factors
for mortality are listed in Table 4. The OR values for every
parameter were used to develop the IMPRES. Since not all
of the parameters would have the same effect on mortality,
we utilized the OR values calculated with the logistic
regression analysis in this model, as these values are the
best statistics for representing this difference. Logistic
regression analysis identified the following independent
risk factors: age, pulmonary edema, COPD exacerbation,
interstitial lung disease, acute renal failure, sepsis, metabolic
encephalopathy, neurodegenerative disease, ICU-level
nursing care requirement, type III respiratory failure,
heart failure, lung cancer, cardiac arrest, and conditions
suggesting to the physician that IMV is unlikely to benefit
the patient (e.g., no chance of life-prolonging treatment,
serious comorbidity (one or more), life expectancy shorter
than 6 months, permanent multiorgan failure, low chance
of recovery despite the benefits gained, high treatment
cost in proportion to the benefits gained, terminal stage
chronic disease/malignancy). While ‘ICU-level nursing
care requirement’ and ‘interstitial lung disease’ had the
greatest effects on mortality (increasing mortality risk by
16.7 and 11.9 times, respectively), the presence of ‘COPD
exacerbation’, ‘pulmonary edema’, and ‘heart failure’ had
negative impacts on the score (–0.6-fold, –0.5-fold, and
–0.7-fold, respectively). The scoring for each parameter is
presented in Table 4.
The total score for each patient was calculated using
the OR values of the independent risk factors that were
significant via logistic regression analysis. Cut-off points
were determined for the total score. To determine the cutoff points, two initial categories were formed via receiver
operating characteristic (ROC) analysis. Consequently,
an ordinal structure was applied to further categorize
the groups as low, moderate, high, and very high risk, so
that the mortality rate would increase from the low to the
very high risk groups and differ between the categories.
Accordingly, the following cut-off scores were obtained:
<2, low risk; 2–5, moderate risk; 5.1–8, high risk; >8: very
high risk.
After scoring for all of the risk factors that were found
to be significant via logistic regression analysis, 1463
patients were categorized in an ordinal manner according
to the cut-off scores presented above. Mortality rates were
compared between these risk categories and the results are
given in the Figure.
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Mortality was seen in 26.8% of the 254 patients with a
total score of lower than 2. The mortality rate was 58.2%
among patients with a total score between 2 and 5, 76.3%
among patients with a total score between 5.1 and 8, and
93.3% among patients with a total score of greater than
8. The increase in the mortality rate according to the risk
categories was statistically significant (Figure).
4. Discussion
Physicians experience a dilemma with some patients,
having to decide whether or not to initiate IMV treatment.
Despite the belief that IMV will not benefit the patient, the
physician may feel obligated to intubate the patient due
to the insistence of the patient’s relatives, local-cultural
factors, or judicial pressures. Although indications for
intubation and IMV have been defined, evidence-based
recommendations about patients that will not benefit
from IMV and those that should not be intubated are
still lacking. Therefore, the current study aimed to
determine criteria that can predict which patients will
not benefit from IMV. The main objective of this study
was to determine a method of making rapid and accurate
predictions of mortality/prognosis prior to ICU admission
using simple clinical features and thus to define “priority”
patients for IMV in order to facilitate the more effective
use of available ICU bed capacity.
An ideal scoring system should accurately predict
mortality, and the actual mortality should be close to the
predicted mortality. The calculation should be convenient
and be based on readily available clinical parameters
without the need for advanced laboratory investigation.
Scoring systems designed for the objective assessment
of the clinical severity and prediction of prognosis and
mortality in ICU patients are currently being used for the
standardization of research and for making comparisons
of the quality of care given to ICU patients. Among these,
the APACHE score (I–IV) uses the worst physiological
values measured within 24 h of ICU admission [16–21].
The Sequential (sepsis-related) Organ Failure Assessment
(SOFA) score uses patient data within the first 24 h of ICU
admission and every subsequent 48 h [22], while updated
versions of the Simplified Acute Physiological Score (SAPS
II–III) [23,24] and Mortality Prediction Model (MPM0
I, II, III) use data collected within the first hour of ICU
admission [25–28]. These scoring systems have both
advantages and disadvantages. For example, APACHE
IV was developed with data collected only from hospitals
in the United States and requires complex patient data.
In addition, despite being developed with data collected
from 35 different countries, some regional equations were
developed using a relatively low sample size [24,29]. When
using the existing scoring systems, clinicians should be
aware of the limitations related with their unique patient
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Table 3. Characteristic properties that were significantly different between the nonsurvival and survival groups of patients receiving
IMV treatment.
Total
(n = 1463)

Non-survived
(n = 880)

Survived (n = 583) P-value

Age (years), median

71 (18–101)

73 (18–101)

69 (18–95)

<0.001

Height [10cm], median

168 (100–190)

168 (110–190)

170 (100–190)

0.034

Weight (kg), median

75 (32–160)

75 (32–160)

75 (35–149.5)

0.009

BMI, median

26 (14–76)

26 (14–76)

26 (14–60)

0.046

No

1440

872 (60.6)

568 (39.4)

Yes

23

8 (34.8)

15 (65.2)

No

1421

864 (60.8)

557 (39.2)

Yes

42

16 (38.1)

26 (61.9)

No

1284

755 (58.8)

529 (41.2)

Yes

179

125 (69.8)

54 (30.2)

No

1371

835 (60.9)

536 (39.1)

Yes

92

45 (48.9)

47 (51.1)

No

1216

758 (62.3)

458 (37.7)

Yes

247

122 (49.4)

125 (50.6)

No

1436

855 (59.5)

581 (40.5)

Yes

27

25 (92.6)

2 (7.4)

No

1386

814 (58.7)

572 (41.3)

Yes

77

66 (85.7)

11 (14.3)

No

1234

711 (57.6)

523 (42.4)

Yes

229

169 (73.8)

60 (26.2)

No

1361

809 (59.4)

552 (40.6)

Yes

102

71 (69.6)

31 (30.4)

No

1298

752 (57.9)

546 (42.1)

Yes

165

128 (77.6)

37 (22.4)

No

1437

873 (60.8)

564 (39.2)

Yes

26

7 (26.9)

19 (73.1)

No

1437

857 (59.6)

580 (40.4)

Yes

26

23 (88.5)

3 (11.5)

No

1437

855 (59.5)

582 (40.5)

Yes

26

25 (96.2)

1 (3.8)

No

1281

786 (61.4)

495 (38.6)

Yes

182

94 (51.6)

88 (48.4)

No

1298

766 (59)

532 (41)

Yes

165

114 (69.1)

51 (30.9)

No

1398

822 (58.8)

576 (41.2)

Yes

65

58 (89.2)

7 (10.8)

No

1355

800 (59)

555 (41)

Yes

108

80 (74.1)

28 (25.9)

Variable
Demographics

Indication for admission
Thoracic trauma
Multiple trauma
Cardiac arrest

Pulmonary edema
COPD exacerbation
Pulmonary hypertension
Pulmonary malignancy
Acute renal failure
Chronic renal failure
Sepsis
Neurodegenerative disease
Oncological solid tumor
ICU-level nursing care requirement

0.017
0.003
0.005
0.023
<0.001
<0.001
<0.001
<0.001
0.043
<0.001
<0.001
<0.001
<0.001

Comorbidity
None
Arrhythmia
Lung cancer
Chronic renal failure

0.012
0.013
< 0.001
0.002
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Table 3. (Continued).
Hematological cancer

No

1448

867 (59.9)

581 (40.1)

Yes

15

13 (86.7)

2 (13.3)

State hospital

220

134 (60.9) a

86 (39.1)

Teaching hospital

530

301 (56.8) b

229 (43.2)

University hospital

639

415 (64.9) a

224 (35.1)

Private hospital

74

30 (40.5) c

44 (59.5)

SOFA, median

9 (1–32)

10 (1–32)

8 (1–28)

<0.001

APACHE, median

26 (1–67)

28 (2–53)

23 (1–67)

<0.001

MV duration, median

7 (1–369)

6 (1–121)

8 (1–369)

<0.001

ICU duration, median

10 (1–369)

8.5 (1–122)

13 (1–369)

<0.001

0.023

Hospital type

<0.001

ICU score

End point

Data are given as n (%) unless otherwise indicated.
Data are presented as median (minimum–maximum) unless otherwise indicated.
a, b, c: Binary chi-square test results indicate statistical differences.
P < 0.05 indicates a statistically significant difference.
BMI: Body mass index, COPD: chronic obstructive lung disease, APACHE-II: Acute Physiology and Chronic Health Evaluation-II,
SOFA: Sequential Organ Failure Assessment, MV: mechanical ventilation, ICU: intensive care unit.

populations. For instance, SAPS-III yields relatively
lower mortality rates for patients with cancer or solid
organ transplants, whereas SOFA can be more helpful in
a population with sepsis [30–32]. The present study was
unique in that it included a large number of patients from
various geographical areas of Turkey who were admitted
to various types of ICUs, had diverse diagnoses and
comorbidities, were intubated with various indications
in either urgent or elective settings, and were followed
by physicians from various specialties. Therefore, we
believe that our data are more general and can be applied
to a broader population. Moreover, the existing scoring
systems do not allow for the prediction of mortality based
only on the patient’s simple clinical findings; rather, they
require further laboratory investigations and 24–48 h of
monitoring. However, physicians who are uncertain of
whether or not to intubate require a rapid and accurate
prediction of mortality based on simple clinical findings.
Unfortunately, the scoring systems mentioned above do
not completely satisfy this need. Indeed, we believe that
our simple scoring system (IMPRES, Invasive Mechanical
Ventilation Mortality Prediction Score), which was
developed based on the available data, may satisfy this
need. One unique feature of the IMPRES scoring system
is that it also takes the physician’s anticipations and
personal experiences into account in the prediction of
prognosis/mortality. Rather than being a laboratory-based
calculation, this scoring system prioritizes the patient’s
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primary diagnosis and acute needs requiring intensive
care. Additionally, in the current study, the APACHE-II
and SOFA scores were significantly higher in the mortality
group, as expected (P < 0.001).
Many published studies have evaluated the factors
associated with mortality in ICU patients. Lee et al. found
that age, sex, Deyo–Charlson comorbidity index, teaching
hospital, hospital level, hospital volume, and physician
volume were significantly associated with mechanical
ventilation outcome (P < 0.001). The ICU patient
population generally consists of elderly patients. In our
current study, the median age of the whole study group
was 71 (18–101) years, and 67.9% of these patients were
older than 65 years. One population-based cohort study
from Taiwan retrospectively analyzed 213,945 patients.
In this large series, all of the patients had a mechanical
ventilation requirement, and 79.7% were over 65 years old
[33]. One study from the United States reported that 48%
of ICU patients were over 65 years old, while this rate was
38% in a study conducted in Paris [34,35]. The reason that
our current study and the study from Taiwan had such
high rates of elderly patients may be because these studies
only included patients receiving IMV. Patients receiving
IMV support are generally older because the incidence
of acute respiratory failure increases significantly with
every 10-year increment in age until age 85. Indeed, the
incidence of acute respiratory failure in the age group of
65–84 years is 2 times higher than that of patients aged 55–

ÖZLÜ et al. / Turk J Med Sci
Table 4. IMV Mortality Prediction Score (IMPRES).
Parameter

Points

Demographics
Age 70 years or older

1.6

Primary indication for admission
Pulmonary edema

–0.5

COPD

–0.6

Interstitial lung disease

11.9

Acute renal failure

1.7

Sepsis

2.2

Metabolic encephalopathy

–0.3

Neurodegenerative diseases

–0.2

ICU-level nursing care requirement

16.7

Acute indication for ICU admission
Type III respiratory failure

–0.3

Comorbidities
Heart failure

–0.7

Lung cancer

3.7

Indication for intubation
Cardiac arrest

1.9

Feature suggesting that MVI is unlikely to benefit
Lack of life-prolonging treatment chance

2.3

Serious comorbidity (one or more)

2.3

Life expectancy shorter than 6 months

3.0

Permanent multiorgan failure

2.4

Low chance of recovery despite the benefits gained

1.9

High treatment cost in proportion to the benefits gained –0.3
Terminal stage chronic disease/malignancy

2.8

<2: Low risk, 2–5: moderate risk, 5.1–8: high risk, >8: very high
risk.
COPD: Chronic obstructive pulmonary disease, ICU: intensive
care unit.

64 years and 3 times higher than that of younger patients
[36]. Previous studies have reported that age over 85 years
is an independent factor for not being accepted to the ICU.
However, there is still no global consensus regarding the
admission of elderly patients (over 70–80 years) to the ICU
[37].
Of our total study patients, 60.2% died during their
ICU stay. Such a high mortality rate can be explained by
the fact that this study had high average ICU APACHEII and SOFA scores, and all of the patients included in
this study had a mechanical ventilation requirement.
General adult ICU mortality rates in the literature vary
between 30% and 65% depending on the selected patient

population [1–5]. Many previous studies have found that
acute organ dysfunction is associated with short-term ICU
mortality [38,39]. A review of the available data shows that
there is much heterogeneity in ICU admission criteria. The
heterogeneous group of patients included in the present
study enabled us to examine the predictive values of many
diagnoses in relation to IMV prognosis. For example,
patients with pulmonary edema, COPD exacerbation,
metabolic encephalopathy, and neurodegenerative
diseases benefitted from mechanical ventilation. Knowing
the predictive value of a patient’s primary diagnosis when
deciding on IMV or ICU admission would be quite helpful
for triage, or the sorting of patients considering their
chance of recovery. Patients have ICU admission priority
if they have severely disturbed overall conditions, are
unstable, and require advanced monitoring and treatment
that cannot be provided outside of the ICU. Patients
with ICU admission priority include postoperative
patients requiring ventilator support and treatments
such as vasoactive drug infusion and patients with acute
respiratory failure, hemodynamic instability, shock, severe
sepsis or sepsis-septic shock, severe trauma, and hypoxia
or hypotension [27,28]. There are ongoing discussions as
to whether patients admitted to the ICU should have a
reasonable survival expectancy and whether the patient
should possess a neuropsychiatric status that is sufficient
to comprehend this support. In fact, this opinion was
expressed in the joint consensus statement of the Society of
Critical Care Medicine [10] Ethics Committee as follows:
“The primary goal of intensive care is to provide treatment
to a patient with a reasonable survival expectancy beyond
the acute treatment, who has adequate cognitive skills
to comprehend the benefits of treatment. Intensive care
interventions should be regarded as futile when there is
no reasonable expectation that the patient will recover
to survive beyond the acute care, or when the patient’s
neurological functions are not fit to perceive the benefits
of treatment” [40]. However, these recommendations are
not based on any legislative regulations in Turkey, nor in
many other countries.
Physicians facing problems associated with the
allocation of ICU beds for patients with low survival
expectancy do not currently have the scientific evidence to
aid in identifying the priority patients that they require in
the face of ethics and the law. Even if a physician believes
that IMV is not likely to be of any benefit to a patient,
he or she may feel obliged to intubate the patient due to
the lack of scientific evidence. Nevertheless, our findings
may need to be verified in specialized ICUs that care for
specific patient populations (e.g., hematopoietic stem cell
transplant patients), or in institutions or regions where
a specific disorder is prevalent (e.g., substance abuse,
transplantation).
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Figure. Mortality rates according to risk categories (<2: low risk, 2–5: moderate risk,
5.1–8: high risk, >8: very high risk). x-axis: IMPRES score category, y-axis: rate (%)
of nonsurvival in the groups. *: Each group has a statistically significant difference in
mortality rate (P < 0.001). n = total number of patients in group.

In conclusion, IMPRES takes various data into
account, including the physician’s subjective anticipation
of the patient’s survival. We believe that IMPRES can
help physicians make a correct assessment of the patient
regarding prognosis and survival at the bedside prior to
deciding whether or not to intubate without requiring any
further time-consuming investigations. In consideration
of our heterogeneous study population, we believe that
IMPRES can be used without influence arising from the
type of ICU or the differences in patient populations.
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